Drugs / 177Lu-TLX250
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05868174 | May 2023 → Dec 2024 overdue | renal cell carcinoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-TLX250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05868174 ↗ |
| Route | Intravenous | “All subjects will receive 177Lu-TLX250 intravenously on day 1” NCT05868174 ↗ |